I
Ian L P Beales
Researcher at Norfolk and Norwich University Hospital
Publications - 135
Citations - 3024
Ian L P Beales is an academic researcher from Norfolk and Norwich University Hospital. The author has contributed to research in topics: Medicine & Gastrin. The author has an hindex of 30, co-authored 117 publications receiving 2648 citations. Previous affiliations of Ian L P Beales include University of East Anglia & Michigan State University.
Papers
More filters
Journal ArticleDOI
Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways.
Ian L P Beales,John Calam +1 more
TL;DR: IL-1β and TNF-α seem to inhibit parietal cell acid secretion by multiple pathways; the inhibition occurs at postreceptor level and involves pertussis toxin and tyrosine kinase dependent and independent pathways.
Journal ArticleDOI
Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation.
TL;DR: Leptin stimulates cell proliferation and inhibits apoptosis in OAC cells via ERK, p38 MAPK, phosphatidylinositol 3'-kinase/Akt, and JAK2-dependent activation of COX-2 and PGE2 production and may contribute to the greatly increased risk of esophageal adenocarcinoma in obesity.
Journal ArticleDOI
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
TL;DR: Statins inhibit proliferation and induce apoptosis in EAC cells via inhibition of Ras farnesylation and inhibition of the ERK and Akt signaling pathways.
Journal ArticleDOI
Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells
TL;DR: AdiponECTin has pro-proliferative and pro-inflammatory actions on colonic epithelial cells; these appear to be differentially activated by the adiponectin isoforms.
Journal ArticleDOI
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan,Silvio Danese,Edward V. Loftus,Severine Vermeire,Stefan Schreiber,Timothy E Ritter,Ronald Fogel,Rajiv Mehta,Sandeep Nijhawan,Radosław Kempiński,Rafał Filip,Ihor Hospodarskyy,Ursula Seidler,Frank Seibold,Ian L P Beales,Hyo Jong Kim,John McNally,Chohee Yun,Sally Zhao,Xiaopeng Liu,Chia Hsiang Hsueh,Chantal Tasset,R. Besuyen,Mamoru Watanabe,William J. Sandborn,Gerhard Rogler,Toshifumi Hibi,Laurent Peyrin-Biroulet +27 more
TL;DR: In this article, the authors evaluated the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, for treatment of ulcerative colitis.